Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 3;12(3):629.
doi: 10.3390/diagnostics12030629.

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin's Lymphomas

Yuliya A Veryaskina  1 , Sergei E Titov  2   3 , Igor B Kovynev  4 , Tatiana I Pospelova  4 , Igor F Zhimulev  2
Affiliations

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin's Lymphomas

Yuliya A Veryaskina et al. Diagnostics (Basel). .

Abstract

Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of malignant lymphomas that can occur in both lymph nodes and extranodal sites. Bone marrow (BM) is the most common site of extranodal involvement in NHL. The objective of this study is to determine the unique profile of miRNA expression in BM affected by NHL, with the possibility of a differential diagnosis of NHL from reactive BM changes and acute leukemia (AL). A total of 180 cytological samples were obtained by sternal puncture and aspiration biopsy of BM from the posterior iliac spine. All the cases were patients before treatment initiation. The study groups were NHL cases (n = 59) and AL cases (acute lymphoblastic leukemia (n = 25) and acute myeloid leukemia (n = 49)); the control group consisted of patients with non-cancerous blood diseases (NCBDs) (n = 48). We demonstrated that expression levels of miRNA-124, miRNA-221, and miRNA-15a are statistically significantly downregulated, while the expression level of let-7a is statistically significantly upregulated more than 2-fold in BM in NHL compared to those in AL and NCBD. ROC analysis revealed that let-7a/miRNA-124 is a highly sensitive and specific biomarker for a differential diagnosis of BM changes in NHL from those in AL and NCBD. Therefore, we conclude that analysis of miRNA expression levels may be a promising tool for early diagnosis of NHL.

Keywords: Non-Hodgkin’s lymphomas; acute leukemia; bone marrow; let-7a; miRNA-124; microRNA.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interest.

Figures

Figure 1
Figure 1
Comparative analysis of miRNA expression levels among non-Hodgkin’s lymphomas, acute leukemia, and non-cancerous blood diseases (NCBDs). The figure presents the median value, upper and lower quartiles, non-outlier range, and outliers appearing as circles.
Figure 1
Figure 1
Comparative analysis of miRNA expression levels among non-Hodgkin’s lymphomas, acute leukemia, and non-cancerous blood diseases (NCBDs). The figure presents the median value, upper and lower quartiles, non-outlier range, and outliers appearing as circles.
Figure 2
Figure 2
ROC Curves for miRNA-124, miRNA-221, miRNA-15a, and let-7a in differential diagnosis of BM changes in NHL from those in AL and NCBD. The ROC curve of miR-124 (A), miR-221 (B), miR-15a (C), let-7a (D), and let-7a/miR-124 combination (E).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Singh R., Shaik S., Negi B.S., Rajguru J.P., Patil P.B., Parihar A.S., Sharma U. Non-Hodgkin’s lymphoma: A review. J. Fam. Med. Prim. Care. 2020;9:1834–1840. - PMC - PubMed
    1. International Non-Hodgkin’s Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl. J. Med. 1993;329:987–994. doi: 10.1056/NEJM199309303291402. - DOI - PubMed
    1. Park Y., Park B.B., Jeong J.Y., Kim W.Y., Jang S., Shin B.K., Lee D.S., Han J.H., Park C.J., Suh C., et al. Assessment of bone marrow involvement in patients with lymphoma: Report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party. Korean J. Intern. Med. 2016;31:1030–1041. doi: 10.3904/kjim.2015.006. - DOI - PMC - PubMed
    1. Fend F., Kremer M. Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy. Pathobiology. 2007;74:133–143. doi: 10.1159/000101712. - DOI - PubMed
    1. Albano D., Patti C., Lagalla R., Midiri M., Galia M. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J. Magn. Reason. Imaging. 2017;45:1082–1089. doi: 10.1002/jmri.25439. - DOI - PubMed

LinkOut - more resources